Geneoscopy, a BioGenerator portfolio company, just reached a major milestone. Widely recognized as a gold standard in oncology and public health, the American Cancer Society (ACS) guidelines play a critical role in shaping cancer screening practices nationwide. The addition of the ColoSense® test as a preferred option marks a significant step forward for both the company and the future of noninvasive cancer screening.
Read More at